UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 29

Sortiert nach

In chronic lymphocytic leukemia, activation of the thrombopoietin receptor promotes T‐cell inhibitory properties, contributing to immunosuppression

European journal of haematology, 2023-04, Vol.110 (4), p.371-378

2023

Volltextzugriff (PDF)

Response rates of extra‐nodal diffuse large B cell lymphoma to anti‐CD19‐CAR T cells: A real word retrospective multicenter study

European journal of haematology, 2023-07, Vol.111 (1), p.63-71

2023

Volltextzugriff (PDF)

ERK Activity in Immature Leukemic Cells Drives Clonal Selection during Induction Therapy for Acute Myeloid Leukemia

Scientific reports, 2020-05, Vol.10 (1), p.8349, Article 8349

2020

Volltextzugriff (PDF)

Effective elimination of high-dose methotrexate by repeated hemodiafiltration and high-flux hemodialysis in patients with acute kidney injury

Journal of oncology pharmacy practice, 2022-03, Vol.28 (2), p.508-515

2022

Volltextzugriff (PDF)

Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies

Haematologica (Roma), 2022-03, Vol.107 (3), p.715

2022

Volltextzugriff (PDF)

Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL—a matched cohort analysis

Annals of hematology, 2022-04, Vol.101 (4), p.755-762

2022

Volltextzugriff (PDF)

Immune dysfunction complexity in chronic lymphocytic leukemia ‒ an issue to consider when designing novel therapeutic strategies

Leukemia & lymphoma, 2020-07, Vol.61 (9), p.2050-2058

Ringelstein-Harlev, Shimrit

2020

Volltextzugriff (PDF)

Third BNT162b2 mRNA SARS-CoV-2 Vaccine Dose Significantly Enhances Immunogenicity in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

Vaccines (Basel), 2023-03, Vol.11 (4), p.775

2023

Volltextzugriff (PDF)

Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia

Leukemia, 2020-01, Vol.34 (1), p.293-295

2020

Volltextzugriff (PDF)

Minimal residual disease surveillance in chronic lymphocytic leukemia by fluorescence-activated cell sorting

Rambam Maimonides medical journal, 2014-10, Vol.5 (4), p.e0027-e0027

2014

Volltextzugriff (PDF)

Patients with Hodgkin Lymphoma Develop Adequate Humoral Serological Response to Vaccination with Two Doses of BNT162b2

Blood, 2021-11, Vol.138 (Supplement 1), p.2458-2458

2021

Volltextzugriff (PDF)

Clinical Features, Laboratory Characteristics, and Response to Therapy in Patients with Acute Undifferentiated Leukemia

Blood, 2018-11, Vol.132 (Supplement 1), p.1505-1505

2018

Volltextzugriff (PDF)

Compromised activity of natural killer cells in diffuse large b-cell lymphoma is related to lymphoma-induced modification of their surface receptor expression

Cancer Immunology, Immunotherapy, 2023-03, Vol.72 (3), p.707-718

2023

Volltextzugriff (PDF)

Administration of Obinutuzumab, and Not Rituximab, during Induction and Maintenance for Follicular Lymphoma Increases the Likelihood of Developing Delayed Neutropenia

Blood, 2022-11, Vol.140 (Supplement 1), p.6534-6535

2022

Volltextzugriff (PDF)

Acceleration of non-Hodgkin lymphoma progression during pregnancy in a murine model

Leukemia & lymphoma, 2024-05, p.1-4

2024

Volltextzugriff (PDF)

Prognostic Impacts of Age, Diagnosis Time, and Relapses in Primary CNS Lymphoma

Journal of clinical medicine, 2024-08, Vol.13 (16), p.4745

2024

Volltextzugriff (PDF)

Chronic lymphocytic leukemia cells acquire regulatory B-cell properties in response to TLR9 and CD40 activation

Cancer Immunology, Immunotherapy, 2018-05, Vol.67 (5), p.739-748

2018

Volltextzugriff (PDF)

Daratumumab in Combination with Vincristine or Nelarabine As Effective Salvage Therapy for Patients with Acute Lymphoblastic Leukemia at High Risk of Relapse

Blood, 2018-11, Vol.132 (Supplement 1), p.5206-5206

2018

Volltextzugriff (PDF)

Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study

Blood, 2022-11, Vol.140 (Supplement 1), p.3816-3817

2022

Volltextzugriff (PDF)

Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience

Leukemia & lymphoma, 2021-01, Vol.62 (1), p.118-124

2021

Volltextzugriff (PDF)

Single agent oral selinexor as a key to potential cure in refractory diffuse large B-cell lymphoma: case report and literature review

American journal of blood research, 2021-01, Vol.11 (1), p.111-117

2021

Volltextzugriff (PDF)

Radiation-Free Protocol for Patients with Acute Lymphoblastic Leukemia and Mixed Phenotype Acute Leukemia Undergoing Induction Chemotherapy and Allogeneic Hematopoietic Cell Transplantation - a Multicenter Historical Prospective Study

Blood, 2019-11, Vol.134 (Supplement_1), p.5654-5654

2019

Volltextzugriff (PDF)

Chronic Lymphocytic Leukemia Cells Acquire a Regulatory B-Cell Phenotype Modified By PD1 Signaling

Blood, 2014-12, Vol.124 (21), p.3319-3319

2014

Volltextzugriff (PDF)

TLR9-Regulated IL10 Mediates Immune Inhibitory Activity of Chronic Lymphocytic Leukemia B-Cells

Blood, 2016-12, Vol.128 (22), p.4377-4377

2016

Volltextzugriff (PDF)

Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data

Blood, 2019-11, Vol.134 (Supplement_1), p.5321-5321

2019

Volltextzugriff (PDF)

1 – 25 von 29

Suche als RSS-Feed

Aktive Filter

PublikationsformBücher

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(27)
Berichte
(2)

Sprache

Englisch
(29)

Erscheinungsjahr

n.n

Thema

Science & Technology
(15)
Life Sciences & Biomedicine
(14)
Hematology
(9)
Humans
(9)
Oncology
(9)
Chronic Lymphocytic Leukemia
(4)
Leukemia
(4)
Lymphocytes T
(4)
B-Cell Lymphoma
(3)
Immunology
(3)
Lymphocytes B
(3)
Lymphoma
(3)
Medicine
(3)
Medicine & Public Health
(3)
Original Article
(3)
Patients
(3)
Acute Myeloid Leukemia
(2)
Aged
(2)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(2)
Cancer Research
(2)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

In chronic lymphocytic leukemia, activation of the thrombopoietin receptor promotes T‐cell inhibitory properties, contributing to immunosuppression

Response rates of extra‐nodal diffuse large B cell lymphoma to anti‐CD19‐CAR T cells: A real word retrospective multicenter study

ERK Activity in Immature Leukemic Cells Drives Clonal Selection during Induction Therapy for Acute Myeloid Leukemia

Effective elimination of high-dose methotrexate by repeated hemodiafiltration and high-flux hemodialysis in patients with acute kidney injury

Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies

Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL—a matched cohort analysis

Immune dysfunction complexity in chronic lymphocytic leukemia ‒ an issue to consider when designing novel therapeutic strategies

Third BNT162b2 mRNA SARS-CoV-2 Vaccine Dose Significantly Enhances Immunogenicity in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia

Minimal residual disease surveillance in chronic lymphocytic leukemia by fluorescence-activated cell sorting

Patients with Hodgkin Lymphoma Develop Adequate Humoral Serological Response to Vaccination with Two Doses of BNT162b2

Clinical Features, Laboratory Characteristics, and Response to Therapy in Patients with Acute Undifferentiated Leukemia

Compromised activity of natural killer cells in diffuse large b-cell lymphoma is related to lymphoma-induced modification of their surface receptor expression

Administration of Obinutuzumab, and Not Rituximab, during Induction and Maintenance for Follicular Lymphoma Increases the Likelihood of Developing Delayed Neutropenia

Acceleration of non-Hodgkin lymphoma progression during pregnancy in a murine model

Prognostic Impacts of Age, Diagnosis Time, and Relapses in Primary CNS Lymphoma

Chronic lymphocytic leukemia cells acquire regulatory B-cell properties in response to TLR9 and CD40 activation

Daratumumab in Combination with Vincristine or Nelarabine As Effective Salvage Therapy for Patients with Acute Lymphoblastic Leukemia at High Risk of Relapse

Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study

Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience

Single agent oral selinexor as a key to potential cure in refractory diffuse large B-cell lymphoma: case report and literature review

Radiation-Free Protocol for Patients with Acute Lymphoblastic Leukemia and Mixed Phenotype Acute Leukemia Undergoing Induction Chemotherapy and Allogeneic Hematopoietic Cell Transplantation - a Multicenter Historical Prospective Study

Chronic Lymphocytic Leukemia Cells Acquire a Regulatory B-Cell Phenotype Modified By PD1 Signaling

TLR9-Regulated IL10 Mediates Immune Inhibitory Activity of Chronic Lymphocytic Leukemia B-Cells

Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data

Aktive Filter

Suchergebnisse filtern